PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26149148-1	2015	OBJECTIVE: To investigate the influence of sex on the cough-preventing effect of target-controlled infusion(TCI)of remifentanil during anesthetic emergence.	Remifentanil	115-127	latexin	Homo sapiens	108-111	
23052952-4	2013	The aim of this study is to evaluate the safety and efficacy of sedation with remifentanil target-controlled infusion (Remi-TCI) in patients with spontaneous ventilation undergoing FFB in ICU.	Remifentanil	78-90	latexin	Homo sapiens	124-127	
25233045-0	2015	Effect-site concentration and plasma concentration of remifentanil during TCI are not the same.	Remifentanil	54-66	latexin	Homo sapiens	74-77	
26121800-1	2015	BACKGROUND: Using an algorithm by which the effect-site concentration of propofol (esTEC) necessary for BIS level set from information input from BIS monitor and TCI pump is estimated, the effect of remifentanil on esTEC was investigated.	Remifentanil	199-211	latexin	Homo sapiens	162-165	
22967972-1	2012	OBJECTIVE: To evaluate the feasibility and efficacy of Narcotrend (NT) monitor in monitoring the depth of anesthesia in severely burned patients with target-controlled infusion (TCI) of remifentanil hydrochloride and propofol during perioperative period.	Remifentanil	186-212	latexin	Homo sapiens	178-181	
22967972-5	2012	All patients received TCI of remifentanil hydrochloride and propofol to induce and maintain anesthesia.	Remifentanil	29-55	latexin	Homo sapiens	22-25	
22967972-24	2012	CONCLUSIONS: Application of Narcotrend monitor in monitoring the depth of anesthesia in severely burned patients during perioperative period with TCI of remifentanil hydrochloride and propofol is beneficial to reducing dosage of narcotics and shortening duration of recovery from anesthesia, and it can accurately predict the level of consciousness of patients at the time of withdrawal of anesthesia.	Remifentanil	153-179	latexin	Homo sapiens	146-149	
21703258-8	2011	A 10-muM concentration of fentanyl and other opioids, including 1 muM morphine and 4 muM remifentanil, induced HIF-1alpha protein expression and HIF-1 target gene expression in an opioid receptor-dependent manner in SH-SY5Y cells with activity peaking at 24h.	Remifentanil	89-101	latexin	Homo sapiens	5-8	
22251106-7	2012	Limiting maximal infusion rate during remifentanil TCI suppressed remifentanil-induced cough.	Remifentanil	38-50	latexin	Homo sapiens	51-54	
22251106-7	2012	Limiting maximal infusion rate during remifentanil TCI suppressed remifentanil-induced cough.	Remifentanil	66-78	latexin	Homo sapiens	51-54	
18626707-12	2008	CONCLUSIONS: We demonstrated the success of a multipharmacological treatment including opioid premedication with CR oxycodone used as transition opioid for TCI remifentanil infusion; the treatment group showed lower pain scores and rescue analgesic consumption, shorter time to discharge from recovery room and from surgical ward, and the same incidence of side effects, comparably to controls.	Remifentanil	160-172	latexin	Homo sapiens	156-159	
21441549-2	2011	METHODS: This double-blind, randomized study tested the possibility to obtain a quicker onset of analgesia by using effect-compartment controlled remifentanil patient-controlled analgesia (remifentanil TCI-PCA) than by using i.v.	Remifentanil	146-158	latexin	Homo sapiens	202-205	
21441549-11	2011	CONCLUSIONS: Remifentanil PCA-TCI with a slow and progressive adapted algorithm without any associated premedication or co-medication is feasible in young healthy women undergoing UAE.	Remifentanil	13-25	latexin	Homo sapiens	30-33	
21600128-0	2011	[Effect of pediatric TCI system for propofol plus remifentanil in pediatric short-duration surgery with laryngeal mask airway anesthesia].	Remifentanil	50-62	latexin	Homo sapiens	21-24	
21600128-1	2011	OBJECTIVE: To study the effect of a pediatric TCI patent system for propofol plus remifentanil in pediatric short-duration surgery with laryngeal mask airway (LMA) anesthesia.	Remifentanil	82-94	latexin	Homo sapiens	46-49	
21600128-11	2011	CONCLUSION: The patented system for propofol 3 microg/ml effect compartment concentration plus remifentanil 2.5 ng/ml plasma concentration TCI displays stable hemodynamics, less stress, fewer complications and better clinical outcomes in pediatric short-duration surgery with LMA anesthesia.	Remifentanil	95-107	latexin	Homo sapiens	139-142	
17486919-1	2007	BACKGROUND: During total intravenous anaesthesia, the target controlled infusion concentration of remifentanil can be achieved either in limiting maximum plasma concentration (Cp) to the effect site target concentration which corresponds to a plasma TCI technique (pTCI) or as fast as possible to achieve the effect-site target without limiting Cp (eTCI).	Remifentanil	98-110	latexin	Homo sapiens	250-253	
18027600-6	2007	In the near future, the introduction of reliable delivery systems for remifentanil combined with propofol would provide us with a new concept in intravenous anesthesia, the DOUBLE TCI Anesthesia.	Remifentanil	70-82	latexin	Homo sapiens	180-183